An adenovirus-vectored recombinant vaccine confers passive immunity protection from swine acute diarrhea syndrome coronavirus challenge in neonatal mice

Swine acute diarrhea syndrome coronavirus (SADS-CoV), an emerging bat-origin Alphacoronavirus with demonstrated zoonotic potential, poses a significant threat to swine health and has considerable economic implications. Currently, no licensed vaccines are available. We constructed a replication-deficient human adenovirus type 5 (Ad5) vectored vaccine candidate, rAd5-SADS-S, which expresses the SADS-CoV spike (S) glycoprotein. The rAd5-SADS-S vaccine elicited robust SADS-CoV-specific humoral immunity and potent cellular responses in both mice and pigs. Notably, rAd5-SADS-S conferred passive protection to neonatal mice against lethal SADS-CoV challenge. These findings establish a preclinical foundation for the development of SADS-CoV vaccines.

Authors

Institutions

Publication Details

Journal
Virologica Sinica
Published
2025-12-01
DOI
https://doi.org/10.1016/j.virs.2025.12.007
Primary Topic
Animal Virus Infections Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

An adenovirus-vectored recombinant vaccine confers passive immunity protection from swine acute diarrhea syndrome coronavirus challenge in neonatal mice

Cong Yuan, Yu Zhang, Juan Zhang, Yueyue Duan et al.
Virologica Sinica
Animal Virus Infections Studies
article

An adenovirus-vectored recombinant vaccine confers passive immunity protection from swine acute diarrhea syndrome coronavirus challenge in neonatal mice

Cong Yuan, Yu Zhang, Juan Zhang, Yueyue Duan, Xueliang Zhu, Qi Wang, Haixue Zheng, Lei Shi, Luyao Li, Wei Mao, Maowen Sun
article en

Abstract

Swine acute diarrhea syndrome coronavirus (SADS-CoV), an emerging bat-origin Alphacoronavirus with demonstrated zoonotic potential, poses a significant threat to swine health and has considerable economic implications. Currently, no licensed vaccines are available. We constructed a replication-deficient human adenovirus type 5 (Ad5) vectored vaccine candidate, rAd5-SADS-S, which expresses the SADS-CoV spike (S) glycoprotein. The rAd5-SADS-S vaccine elicited robust SADS-CoV-specific humoral immunity and potent cellular responses in both mice and pigs. Notably, rAd5-SADS-S conferred passive protection to neonatal mice against lethal SADS-CoV challenge. These findings establish a preclinical foundation for the development of SADS-CoV vaccines.

Virologica SinicaVol. 40(6)
Lanzhou Institute of Chemical Physics (CN), Lanzhou Veterinary Research Institute (CN), Chinese Academy of Agricultural Sciences (CN), Sichuan Academy of Agricultural Sciences (CN)
Openalex Percentile: Top 55%
Animal Virus Infections Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

An adenovirus-vectored recombinant vaccine confers passive immunity protection from swine acute diarrhea syndrome coronavirus challenge in neonatal mice — Cong Yuan, Yu Zhang, et al. · Virologica Sinica (2025) | TGRS Research Map | TGRS